The combo therapy demonstrated an ORR of 87%, with a complete response rate of 65% and a partial response rate of 23%.

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

Phosphorylation by CDK-2-cyclin E complex prevents this inhibition and so progression from G1 to S phase can continue. Overall, cyclins are responsible for the progression of the cell cycle ...

Bila Solar has started module production in Indiana and T1 Energy is preparing to build a 5 gigawatt, $850M solar cell ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Novartis Fabhalta shows statistically significant and clinically meaningful improvements in haemoglobin in new population of patients with PNH: Basel Friday, June 13, 2025, 09:00 ...

Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP ...

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC), the ...

Officials said $69.2 million is committed to the project to date. Benoit told MLAs that the first phase of the program will see Rogers have almost 20 of 27 existing structures upgraded by the end ...

This cascade culminated in G0/G1 phase cell cycle arrest. Furthermore, analysis of TCGA-HCC datasets confirmed inverse correlations between PPP1R12B and PAK2 or CTNNB1 (β-catenin) expression.